-
Mashup Score: 83
– AJ1-11095 is the first Type II JAK2 Inhibitor to enter the clinic – – Preclinically, AJ1-11095 has demonstrated superior efficacy to Type I JAK2 inhibitors, such as ruxolitinib, with disease modifying effects on mutant allele burden and fibrosis – New York, NY and Cambridge, MA, October 30, 2024 – Ajax Therapeutics, Inc., a biopharmaceutical […]
Source: www.ajaxtherapeutics.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 63Nobel prize for medicine goes to the pair who discovered microRNA - 3 month(s) ago
The 2024 Nobel prize in physiology or medicine has gone to Victor Ambros and Gary Ruvkun for their work on discovering microRNA and its role in post-transcriptional gene regulation
Source: www.newscientist.comCategories: General Medicine News, Hem/OncsTweet-
Well, @MassGenBrigham / @harvardmed and @UMass media relations are about to have a very busy day. MicroRNA this year. Congratulations to Gary Ruvkun and Victor Ambros. https://t.co/jMhLUqqTWC
-
-
Mashup Score: 10Biomarker-Driven Personalized Immunoprevention: Toward More Efficient Clinical Trials? - 3 month(s) ago
Abstract. In this secondary analysis of specimens from the CANTOS trial, the investigators find that patients with clonal hematopoiesis mutations, particularly in the TET2 gene, predict a benefit of decreased cancer risk with the administration of the anti-IL1β agent canakinumab. Despite small numbers and the need for prospective validation, the findings are exciting as they demonstrate the potential for personalized chemoprevention approaches. Such personalized approaches can potentially enhance the feasibility of cancer prevention trials.See related article by Woo et al., p. 429
Source: aacrjournals.orgCategories: General Medicine News, Hem/OncsTweet-
The CANTOS solid tumor article was accompanied by a nice Spotlight commentary on implications for "personalized chemoprevention" by SaI Yendamuri @RoswellPark and Konstantin Dragnev @DartmouthHealth. https://t.co/1dm6DPU5fp
-
-
Mashup Score: 10Biomarker-Driven Personalized Immunoprevention: Toward More Efficient Clinical Trials? - 4 month(s) ago
Abstract. In this secondary analysis of specimens from the CANTOS trial, the investigators find that patients with clonal hematopoiesis mutations, particularly in the TET2 gene, predict a benefit of decreased cancer risk with the administration of the anti-IL1β agent canakinumab. Despite small numbers and the need for prospective validation, the findings are exciting as they demonstrate the potential for personalized chemoprevention approaches. Such personalized approaches can potentially enhance the feasibility of cancer prevention trials.See related article by Woo et al., p. 429
Source: aacrjournals.orgCategories: General Medicine News, Hem/OncsTweet-
The CANTOS solid tumor article was accompanied by a nice Spotlight commentary on implications for "personalized chemoprevention" by SaI Yendamuri @RoswellPark and Konstantin Dragnev @DartmouthHealth. https://t.co/1dm6DPU5fp
-
-
Mashup Score: 52Effect of Clonal Hematopoiesis Mutations and Canakinumab Treatment on Incidence of Solid Tumors in the CANTOS Randomized Clinical Trial - 4 month(s) ago
We reveal that administering canakinumab is associated with a decrease in non-hematological malignancies among patients with clonal hematopoiesis (CH) mutations. These findings underscore canakinumab’s potential in preventing cancer and provide proof of IL1β blockade collaborating with CH mutations to enhance its clinical benefits.
Source: aacrjournals.orgCategories: General Medicine News, Hem/OncsTweet-
Our latest analysis (led by Janghee Woo @WinshipAtEmory ) of n=10,061 CANTOS trial published today @AACR CPR: canakinumab-treated patients w/ TET2 mutations had lowest incidence of new non-heme malignancies. Possible role of anti-IL1β in cancer prevention? https://t.co/coLvByQc4C
-
-
Mashup Score: 37Doctor mistakenly removes liver instead of spleen: lawsuit - 4 month(s) ago
The patient’s wife says she is pursuing both civil and criminal cases.
Source: www.newsweek.comCategories: General Medicine News, Hem/OncsTweet-
Splenectomy is a procedure that has risks - bleeding, thrombosis, infection - but accidentally removing the liver instead of the spleen is a new one. How does that happen?! What a catastrophe. Condolences to the patient’s family. https://t.co/SVAG9PR9eP
-
-
Mashup Score: 5The massive Social Security number breach is actually a good thing - 4 month(s) ago
The social security data breach highlights the risk of identity theft.
Source: www.vox.comCategories: General Medicine News, Hem/OncsTweet-
https://t.co/G26slU1LTV
-
-
Mashup Score: 26Sonic Diagnosis - 4 month(s) ago
The sounds our bodies make can tell doctors all kinds of surprising things about our health. In this episode, we unpack the history of sound in medical diagnosi
Source: podcasts.apple.comCategories: General Medicine News, Hem/OncsTweet-
One of my favorite podcasts is “Twenty Thousand Hertz”, a celebration of sound. I was interviewed recently for the latest episode, discussing the history & ongoing importance of sound in medicine (eg percussion, auscultation & just listening.) #medtwitter https://t.co/PH2fgdQDzT
-
-
Mashup Score: 7Analysts predict myeloma market will hit $33B by 2030—and tip one company to take the lion's share - 7 month(s) ago
The multiple myeloma market is booming. | The multiple myeloma market is booming. Bloomberg Intelligence (BI) forecasts sales will hit $33 billion in 2030, up almost $10 billion on last year, as Johnson & Johnson wrestles control of the blood cancer market from Bristol Myers Squibb.
Source: www.fiercepharma.comCategories: General Medicine News, Hem/OncsTweet-
@AaronGoodman33 Wonder why https://t.co/SMuSNuGILb
-
-
Mashup Score: 11CHZ868, a Type II JAK2 Inhibitor, Reverses Type I JAK Inhibitor Persistence and Demonstrates Efficacy in Myeloproliferative Neoplasms - 8 month(s) ago
The current clinical JAK2 inhibitors are type I kinase inhibitors that provide clinical benefits to myeloproliferative neoplasm (MPN) patients but do not reduce mutant allele burden. Meyer et al. report a type II JAK2 inhibitor that shows activity against relevant MPN models and reduces mutant allele burden.
Source: www.cell.comCategories: General Medicine News, Hem/OncsTweet-
@AaronGoodman33 @rosslevinemd A problem with type I JAK inhibitors is resistance develops, in part due to heterodimerization with other JAK2 family members (JAK1, TYK2). Idea of a type II inhibitor is based on work in Ross's lab about overcoming that (and also Dave Weinstock in ALL): https://t.co/YDAyJskfJX
-
Ajax @AjaxThx is now a clinical-stage company! First patient with myelofibrosis #MPNsm has been dosed w/ AJ1-11095, the 1st type II JAK2 inhibitor to reach clinical trials. "FPFV" is always such an exciting milestone. Grateful to patients & investigators. https://t.co/4JujbDPiFT